EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Oct 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-10-12

Reporting Person: Ross Leonard S (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-12	Common Stock	A	20000	$0.00	Acquired	34762	Direct
2018-10-12	Common Stock	F	2945	$3.23	Disposed	31817	Direct

Footnotes

F1: On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 10,000 shares representing a previously granted performance stock unit award vested on that date. An additional 10,000 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

F2: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the performance stock units.